Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Short-term Investments (2016 - 2022)

Iradimed (IRMD) has disclosed Short-term Investments for 10 consecutive years, with $500090.0 as the latest value for Q1 2022.

  • On a quarterly basis, Short-term Investments fell 73.72% to $500090.0 in Q1 2022 year-over-year; TTM through Mar 2022 was $500090.0, a 73.72% decrease, with the full-year FY2021 number at $501855.0, down 73.72% from a year prior.
  • Short-term Investments was $500090.0 for Q1 2022 at Iradimed, roughly flat from $501855.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $8.2 million in Q2 2018 to a low of $500090.0 in Q1 2022.
  • A 5-year average of $3.6 million and a median of $2.8 million in 2019 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: increased 16.34% in 2018, then plummeted 73.72% in 2022.
  • Iradimed's Short-term Investments stood at $6.3 million in 2018, then plummeted by 56.4% to $2.8 million in 2019, then plummeted by 31.03% to $1.9 million in 2020, then crashed by 73.72% to $501855.0 in 2021, then dropped by 0.35% to $500090.0 in 2022.
  • Per Business Quant, the three most recent readings for IRMD's Short-term Investments are $500090.0 (Q1 2022), $501855.0 (Q4 2021), and $945066.0 (Q3 2021).